DDInter1814 DDInter1376
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Tioguanine {u} (Compound) treats {v} (Disease) hematologic cancer
Tioguanine {u} (Compound) binds {v} (Gene) IMPDH2
Tioguanine {u} (Compound) causes {v} (Side Effect) Portal hypertension
Tioguanine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Tioguanine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Tioguanine (Compound) resembles Adenine (Compound)
Tioguanine (Compound) treats hematologic cancer (Disease)
Tioguanine (Compound) binds IMPDH2 (Gene)
Tioguanine (Compound) causes Portal hypertension (Side Effect)
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab
Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Tioguanine may lead to a major life threatening interaction when taken with Cladribine
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine